Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Payables: 2010-2025

Historic Payables for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $4.7 million.

  • Anika Therapeutics' Payables fell 30.46% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 38.22%. This contributed to the annual value of $5.6 million for FY2024, which is 9.32% down from last year.
  • Latest data reveals that Anika Therapeutics reported Payables of $4.7 million as of Q3 2025, which was down 0.82% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Payables ranged from a high of $10.0 million in Q1 2024 and a low of $4.7 million during Q3 2025.
  • For the 3-year period, Anika Therapeutics' Payables averaged around $7.1 million, with its median value being $6.8 million (2024).
  • As far as peak fluctuations go, Anika Therapeutics' Payables soared by 31.47% in 2021, and later plummeted by 52.26% in 2025.
  • Over the past 5 years, Anika Therapeutics' Payables (Quarterly) stood at $7.6 million in 2021, then increased by 18.88% to $9.1 million in 2022, then crashed by 31.74% to $6.2 million in 2023, then fell by 9.32% to $5.6 million in 2024, then slumped by 30.46% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q3 2025, $4.8 million for Q2 2025, and $5.3 million during Q1 2025.